文献速递类风湿关节炎

巴瑞替尼类风湿关节炎Ⅲ期试验中FACIT-F与PROMIS疲劳评分的转换评估

Conversion of Functional Assessment of Chronic Illness Therapy-Fatigue to Patient-Reported Outcomes Measurement Information System Fatigue Scores in Two Phase III Baricitinib Rheumatoid Arthritis Trials.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2021-01-01

该研究在RA-BEAM和RA-BEACON两项巴瑞替尼治疗类风湿关节炎的Ⅲ期试验中,采用交叉参照表和模式评分法将13项FACIT-F及10项RA优化FACIT-F转换为PROMIS疲劳T评分。结果显示各转换方法在基线和第24周表现一致,巴瑞替尼较安慰剂自第12周起显示可区分治疗效应的PROMIS疲劳评分改善。

要点

  • 4种转换方法均能区分巴瑞替尼与安慰剂在PROMIS疲劳评分上的差异,自第12周起可见。
  • 13项FACIT-F与10项RA优化FACIT-F转换所得的PROMIS疲劳评分一致。
  • 转换后的PROMIS疲劳评分可用于RA临床试验中标准化评估疲劳及治疗获益。

核心结论

  • 所有4种转换方法均显示活性治疗与安慰剂自第12周起可区分,支持使用PROMIS疲劳评分及将10项FACIT-F转换为标准化指标评估RA临床试验中的疲劳与治疗获益。

研究设计与样本

  • 在评估巴瑞替尼的RA-BEAM和RA-BEACON两项RA临床试验中,采用交叉参照表和模式评分法将13项FACIT-F及10项RA优化FACIT-F转换为PROMIS疲劳评分。
  • RA-BEAM患者对甲氨蝶呤应答不足,RA-BEACON患者对≥1种TNF抑制剂应答不足或不耐受。
  • 通过协方差分析比较巴瑞替尼与所有治疗组在PROMIS疲劳评分转换上的差异。

主要发现

  • 基线时FACIT-F衍生的PROMIS疲劳评分在各治疗组均反映严重疲劳,且不同评分方法所得结果相似。
  • 两项研究第24周时,巴瑞替尼与PROMIS疲劳评分的临床意义改善相关。
  • PROMIS疲劳评分在转换方法间及13项与10项FACIT-F间保持一致。

关键数值与推荐

  • PROMIS疲劳采用经项目反应理论校准的T评分度量。
  • 13项FACIT-F中有10项被识别为与RA患者相关。

临床怎么用

  • 在RA临床试验中,可将10项RA优化FACIT-F转换为PROMIS疲劳T评分,以标准化度量评估疲劳及治疗获益。
  • 转换后的PROMIS疲劳评分可用于比较巴瑞替尼与安慰剂在疲劳改善上的差异。

局限性

  • 转换后PROMIS疲劳评分的性能尚未在RA人群或临床试验中评估,本研究为首次评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) is validated for measuring fatigue in rheumatoid arthritis (RA). However, 10 of 13 FACIT-F items are identified as relevant to patients with RA. The Patient-Reported Outcomes Measurement Information System (PROMIS) uses an item response theory-calibrated T score metric. The PROMIS Fatigue item bank includes the FACIT-F items, enabling score conversion. The performance of converted PROMIS Fatigue scores has not been evaluated in RA populations or clinical trials. Our objective was to assess the performance of converted PROMIS Fatigue scores in 2 RA clinical trials of baricitinib. METHODS: Crosswalk tables and pattern-scoring methods converted FACIT-F scores to PROMIS Fatigue for both the 13-item FACIT-F and the 10-item RA-optimized FACIT-F instrument, in 2 RA clinical trials evaluating baricitinib, RA-BEAM, and RA-BEACON. RA-BEAM patients had an inadequate response to methotrexate. RA-BEACON patients had an inadequate response or intolerance to ≥1 tumor necrosis factor inhibitor. Baricitinib was compared to all treatment arms via analysis of covariance on PROMIS Fatigue score conversions. RESULTS: Baseline FACIT-F-derived PROMIS Fatigue scores reflected severe fatigue across treatment groups and were similar using different scoring methods. At week 24 in both studies, baricitinib was associated with clinically meaningful improvements in PROMIS Fatigue scores. PROMIS Fatigue scores were consistent for conversion methods and for the 13-item or 10-item FACIT-F. CONCLUSION: All 4 conversion methods showed differentiation of active treatment compared with placebo from week 12, supporting the use of the PROMIS Fatigue and converting the 10-item FACIT-F to assess fatigue and demonstrate treatment benefit in RA clinical trials on a standardized metric.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Bingham CO, Bartlett SJ, Kannowski C, et al. Conversion of Functional Assessment of Chronic Illness Therapy-Fatigue to Patient-Reported Outcomes Measurement Information System Fatigue Scores in Two Phase III Baricitinib Rheumatoid Arthritis Trials. Arthritis Care Res (Hoboken). 2021. PMID: 31961494. doi:10.1002/acr.24144

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。